Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, reported half-year 2026 results on August 20, 2026…
August 20, 2026
BlossomHill Therapeutics, Inc. (NASDAQ: BLSM), a clinical-stage biopharmaceutical company developing small molecule cancer medicines, announced terms for its IPO on August 3, 2026. The San…
August 03, 2026
Latigo Biotherapeutics Sets Terms for $272 Million IPO, Backed by NEJM-Published Phase 2 Data for Its Non-Opioid Pain Candidate
Latigo Biotherapeutics, Inc. (NASDAQ: LTGO), a clinical-stage biopharmaceutical company developing oral, selective Nav1.8 inhibitors as non-opioid alternatives for acute and chronic pain, announced terms for…
WAKIX revenue hit a new high and beat expectations. Harmony reaffirmed rather than raised its full-year guidance, implying a flatter back half, and disclosed a…
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic conditions, presented late-breaking Phase 2 data for CAD-1005 at…
Abivax SA ADR (NASDAQ: ABVX), a clinical-stage biotechnology company, released positive results from the ABTECT Maintenance Part 2 trial evaluating obefazimod in ulcerative colitis patients…
Every June, the United States observes Men’s Health Month, an awareness campaign first formalized in 1994 when Congress passed legislation establishing National Men’s Health Week….
June 23, 2026
Definium Therapeutics Achieves Historic Phase 3 Milestone with LSD-Based Depression Treatment
Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company, announced positive topline results from its Phase 3 Emerge study on June 22, 2026. The…
June 15, 2026
Johnson & Johnson Commits Over 1 Billion Dollars to Expand Florida Vision Manufacturing
Johnson & Johnson (NYSE: JNJ) announced a capital allocation plan exceeding $1 billion to expand its vision care manufacturing footprint in Jacksonville, Florida. This long-term…
Eli Lilly and Company (NYSE: LLY) has entered into a collaboration and out‑licensing agreement with Sweden‑based AlzeCure for global rights to Alzstatin ACD680, a preclinical…
Small-cap pharma is where some of the market’s sharpest re-ratings happen, because a single clinical or regulatory milestone can change a company’s trajectory overnight. The…
The first wave of disease-modifying Alzheimer’s drugs is here. Leqembi from Eisai and Biogen. Kisunla from Eli Lilly. Both opened the market. Both also exposed…